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![Distribution of *TP53* codon 72 genotypes among pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatic (CP) patients and normal controls.\
The *p*-value was calculated by comparing the Pro/Pro genotype between PDAC patients and normal controls and between CP patients and normal controls.](pone.0126295.g001){#pone.0126295.g001}

![Distribution of *MDM2* single-nucleotide polymorphism (SNP) 309 genotypes among pancreatic ductal adenocarcinoma (PDAC) patients, chronic pancreatitis (CP) patients and normal controls.\
The *p*-value was calculated by comparing the G/G genotype between PDAC patients and normal controls and between CP patients and normal controls.](pone.0126295.g002){#pone.0126295.g002}
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